Canakinumab effective in treating systemic juvenile idiopathic arthritis .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2013;1(6):57 N Engl J Med. 2012 Dec 20;367(25):2396-406. doi: 10.1056/NEJMoa1205099177 patients, suffering from systemic juvenile idiopathic arthritis (JIA) with active systemic features, who had been chosen to participate in two trials between July 2009 and December 2010, were randomised into two groups to either receive canakinumab or a placebo. Patients in Trial 1 received either canakinumab or the placebo for 29 days. Trial 2 incorporated a two-part withdrawal design, which consisted of an open-label phase, lasting for 32 weeks, and a withdrawal phase. The results demonstrated that the canakinumab was effective in treating systemic JIA following a 29 day and 32 week follow-up period, but had potential to occasionally cause infections.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
